ViiV Healthcare
Présence
GSK fait partie des...
- Forbes Global 2000 (#187);
- Fortune 500 Europe (#81);
- FTSE 350;
- Global Fortune 500 (#343);
- Stoxx 600.
GSK est une société cotée sous le symbole boursier GSK (GB).
GSK a une présence directe dans 21 pays.GSK a 22 filiales dont GSK ANZ, GSK APAC et GSK Austria.
Acquisition, funding and merger involving GSK.
- GSK has announced the acquisition of Aiolos Bio (publié le 12 janvier 2024).
- GSK has announced the acquisition of Bellus Health (publié le 19 avril 2023).
- GSK has announced the acquisition of Affinivax (publié le 1 juin 2022).
Dirigeants
Voir l'organigramme avec ses 22 principaux dirigeants
Biographies les plus recherchées chez ViiV Healthcare
- Deborah Waterhouse, Chief Executive Officer and Director
- Regis Simard, Director
- David Redfern, Chairman of the Board
Changements de dirigeants chez GSK
- Jeannie Lee rejoindra l'entreprise comme Non-Executive Director le 4 mars 2024 (publié le 29 février 2024).
- Wendy Becker rejoindra l'entreprise comme Non-Executive Director le 1 oct. 2023 (publié le 28 septembre 2023).
Créer une alerte
pour suivre les mouvements de dirigeants chez ViiV Healthcare.
Pharmacie
GSK a 1 865 concurrents dont Pfizer (Etats—Unis), Sanofi (France) et Johnson & Johnson (Etats—Unis).
Actualités en fusion/acquisition en Pharmacie.
- AstraZeneca has announced the acquisition of Fusion Pharma (publié le 23 mars 2024).
- AstraZeneca has announced the acquisition of Amolyt Pharma (publié le 19 mars 2024).
- Frontier Medicines vient d'annoncer une levée de fonds de 80 millions de dollars. (publié le 27 février 2024).
Contacts en Pharmacie
Actualités
Derniers communiqués de presse par ViiV Healthcare
- ViiV Healthcare announces new strategic alliance to enable greater access to antiretroviral medicines in Brazil
- ViiV Healthcare announces superior efficacy of investigational, long-acting injectable formulation of cabotegravir dosed every two months over daily oral PrEP
- ViiV Healthcare presents positive data from first-ever implementation research study on how best to integrate a investigational once-monthly injectable HIV treatment in US healthcare practices
- ViiV Healthcare shares new data from Positive Perspectives, Wave 2 study, confirming a more holistic approach to HIV care can improve quality of life
- ViiV Healthcare announces US FDA approval for Rukobia (fostemsavir), a first-in-class treatment for HIV in adults with few treatment options available
- ViiV Healthcare to present new data on long-acting regimens for HIV prevention and treatment, alongside extensive insights into the evolving needs of people living with HIV at 23rd International AIDS Conference (AIDS 2020: Virtual)
- ViiV Healthcare announces grantees selected as part of £3 million Fund dedicated to HIV research and community-based programmes during COVID-19 pandemic
- Welsh Rugby star Gareth Thomas and ViiV Healthcare launch Tackle HIV campaign to address public misunderstanding and stigma associated with HIV
- Global HIV prevention study to stop early after ViiV Healthcare’s long-acting injectable formulation of cabotegravir dosed every two months shows higher efficacy than daily oral PrEP
- ViiV Healthcare announces £3 million global fund to research the impact of COVID-19 on the HIV community and fill gaps in prevention, treatment and care during the pandemic
- Voir plus de communiqués de presse Close
Réseaux sociaux à propos de ViiV Healthcare
- ViiV Healthcare sur Wikipédia, Google News & Yahoo Finance en 1-click
- ViiV Healthcare sur LinkedIn, Twitter & YouTube en 1-click
Entrer en contact
Contacter par email ses dirigeants dont David Redfern 
Appelez ViiV Healthcare au +44 792...
